Feasibility of Capecitabine and Oxaliplatin Combination Chemotherapy Without Central Venous Access Device in Patients With Stage III Colorectal Cancer.

Fiche publication

Date publication

septembre 2016

Journal

Clinical colorectal cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BOUCHE Olivier

Tous les auteurs :
Lapeyre-Prost A, Hug de Larauze M, Chibaudel B, Garcia ML, Guering-Meyer V, Bouché O, Boucher E, Ychou M, Dauba J, Obled S, Lièvre A, Malka D, Faroux R, Bonnet I, Taieb J, André T,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/26752558

Résumé

5-Fluorouracil and leucovorin plus oxaliplatin (FOLFOX) or capecitabine plus oxaliplatin (XELOX) is a standard adjuvant treatment for patients with stage III colon cancer (CC). Capecitabine is an oral fluoropyrimidine, and administration of oxaliplatin does not necessarily require the insertion of a central venous access device (CVAD). We evaluated the feasibility of XELOX without a CVAD as adjuvant treatment in patients with stage III CC.